# US 2016/0252513 A1 · Method, array and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252513 A1
- Document ID: US20160252513A1
- Status: Published application
- Kind: A1
- Application number: 15/035,953
- Filed: 2014-11-11
- Published: 2016-09-01
- Earliest claimed: 2013-11-11
- Assignees: Immunovia AB
- Applicants: Immunovia AB
- Inventors: Carl Arne Krister Borrebaeck; Christer Lars Bertil Wingren
- Web page: https://patentgrep.com/patent/US20160252513A1

## CPC

- G01N 33/57525: of the liver or pancreas
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from an individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table A is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention.

## Claims

### Claim 1

A method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of:
a) providing a sample to be tested from the individual;
b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table A (i), (ii) or (iii);
wherein the expression in the test sample of the one or more biomarker selected from the group defined in Table A (i), (ii) or (iii) is indicative of the presence of pancreatic cancer.

### Claim 2 (depends on 1)

The method according to claim 1 further comprising or consisting of the steps of:
c) providing a control sample from an individual not afflicted with pancreatic cancer;
d) determining a biomarker signature of the control sample by measuring the expression in the control sample of the one or more biomarkers measured in step (b);
wherein the presence of pancreatic cancer is identified in the event that the expression in the test sample of the one or more biomarkers measured in step (b) is different from the expression in the control sample of the one or more biomarkers measured in step (d).

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2 further comprising or consisting of the steps of:
e) providing a control sample from an individual afflicted with pancreatic cancer;
f) determining a biomarker signature of the control sample by measuring the expression in the control sample of the one or more biomarkers measured in step (b);
wherein the presence of pancreatic cancer is identified in the event that the expression in the test sample of the one or more biomarkers measured in step (b) corresponds to the expression in the control sample of the one or more biomarkers measured in step (f).

### Claim 4 (depends on 1, 2, 3)

The method according to claim 1, 2 or 3, wherein step (b) comprises or consists of measuring the expression of one or more of the biomarkers listed in Table A(i), for example, at least 2 of the biomarkers listed in Table IV(A).

### Claim 5

The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of HADH2 and/or TNFRSF3, for example, measuring the expression of HADH2, measuring the expression of TNFRSF3, or measuring the expression of HADH2 and TNFRSF3.

### Claim 6

The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of each the biomarkers listed in Table A(i).

### Claim 7

The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of 1 or more of the biomarkers listed in Table (A)(ii), for example at least 2, 3, 4, 5, 6, 7, 8 or 9 of the biomarkers listed in Table A(ii).

### Claim 8

The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of all of the biomarkers listed in Table A(ii).

### Claim 9

The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of 1 or more biomarkers from the biomarkers listed in Table A(iii), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 of the biomarkers listed in Table A(iii).

### Claim 10

The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of 1 or more biomarkers from the biomarkers listed in Table A(iv), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 of the biomarkers listed in Table A(iv).

### Claim 11

The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of 1 or more biomarkers from the biomarkers listed in Table A(v), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, or 56 of the biomarkers listed in Table A(v).

### Claim 12

The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of 1 or more biomarkers from the biomarkers listed in Table A(vi).

### Claim 13

The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression in the test sample of all of the biomarkers defined in Table A.

### Claim 14

The method according to any one of the preceding claims wherein the pancreatic cancer is selected from the group consisting of adenocarcinoma, adenosquamous carcinoma, signet ring cell carcinoma, hepatoid carcinoma, colloid carcinoma, undifferentiated carcinoma, and undifferentiated carcinomas with osteoclast-like giant cells.

### Claim 15

The method according to any one of the preceding claims wherein the pancreatic cancer is an adenocarcinoma.

### Claim 16

The method according to any one of the preceding claims wherein step (b), (d) and/or step (f) is performed using a first binding agent capable of binding to the one or more biomarkers.

### Claim 17 (depends on 16)

The method according to claim 16 wherein the first binding agent comprises or consists of an antibody or an antigen-binding fragment thereof.

### Claim 18 (depends on 16)

The method according to claim 16 wherein the antibody or antigen-binding fragment thereof is a recombinant antibody or antigen-binding fragment thereof.

### Claim 19 (depends on 16, 17)

The method according to claim 16 or 17 wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of: scFv; Fab; a binding domain of an immunoglobulin molecule.

### Claim 20 (depends on 16, 17, 18, 19)

The method according to any one of claims 16 to 19 wherein the first binding agent is immobilised on a surface.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method according to any one of claims 1 to 20 wherein the one or more biomarkers in the test sample are labelled with a detectable moiety.

### Claim 22 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method according to any one of claims 2 to 20 wherein the one or more biomarkers in the control sample(s) are labelled with a detectable moiety.

### Claim 23 (depends on 21, 22)

The method according to claim 21 or 22 wherein the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety; an enzymatic moiety.

### Claim 24 (depends on 21, 23)

The method according to claim 21 or 23 wherein the detectable moiety is biotin.

### Claim 25 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method according to any one of claims 16 to 24 wherein step (b), (d) and/or step (f) is performed using an assay comprising a second binding agent capable of binding to the one or more biomarkers, the second binding agent comprising a detectable moiety.

### Claim 26 (depends on 25)

The method according to any one of claim 25 wherein the second binding agent comprises or consists of an antibody or an antigen-binding fragment thereof.

### Claim 27 (depends on 26)

The method according to claim 26 wherein the antibody or antigen-binding fragment thereof is a recombinant antibody or antigen-binding fragment thereof.

### Claim 28 (depends on 26, 27)

The method according to claim 26 or 27 wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of: scFv; Fab; a binding domain of an immunoglobulin molecule.

### Claim 29 (depends on 25, 26, 27, 28)

The method according to any one of claims 25 to 28 wherein the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety; an enzymatic moiety.

### Claim 30 (depends on 29)

The method according to claim 29 wherein the detectable moiety is fluorescent moiety (for example an Alexa Fluor dye, e.g. Alexa647).

### Claim 31

The method according to any one of the preceding claims wherein the method comprises or consists of an ELISA (Enzyme Linked Immunosorbent Assay).

### Claim 32

The method according to any one of the preceding claims wherein step (b), (d) and/or step (f) is performed using an array.

### Claim 33 (depends on 32)

The method according to claim 32 wherein the array is a bead-based array.

### Claim 34 (depends on 32)

The method according to claim 32 wherein the array is a surface-based array.

### Claim 35 (depends on 32, 33, 34)

The method according to any one of claims 32 to 34 wherein the array is selected from the group consisting of: macroarray; microarray; nanoarray.

### Claim 36

The method according to any one of the preceding claims wherein the method comprises:
(v) labelling biomarkers present in the sample with biotin;
(vi) contacting the biotin-labelled proteins with an array comprising a plurality of scFv immobilised at discrete locations on its surface, the scFv having specificity for one or more of the proteins in Table A;
(vii) contacting the immobilised scFv with a streptavidin conjugate comprising a fluorescent dye; and
(viii) detecting the presence of the dye at discrete locations on the array surface
wherein the expression of the dye on the array surface is indicative of the expression of a biomarker from Table A in the sample.

### Claim 37

The method according to any one of claims wherein, step (b), (d) and/or (f) comprises measuring the expression of a nucleic acid molecule encoding the one or more biomarkers.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the nucleic acid molecule is a cDNA molecule or an mRNA molecule.

### Claim 39 (depends on 37)

The method according to claim 37, wherein the nucleic acid molecule is an mRNA molecule.

### Claim 40 (depends on 37, 38, 39)

The method according to claim 37, 38 or 39, wherein measuring the expression of the one or more biomarker(s) in step (b), (d) and/or (f) is performed using a method selected from the group consisting of Southern hybridisation, Northern hybridisation, polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), quantitative real-time PCR (qRT-PCR), nanoarray, microarray, macroarray, autoradiography and in situ hybridisation.

### Claim 41 (depends on 37, 38, 39, 40)

The method according to any one of claims 37-40, wherein measuring the expression of the one or more biomarker(s) in step (b) is determined using a DNA microarray.

### Claim 42 (depends on 37, 38, 39, 40, 41)

The method according to any one of claims 37 to 41, wherein measuring the expression of the one or more biomarker(s) in step (b), (d) and/or (f) is performed using one or more binding moieties, each individually capable of binding selectively to a nucleic acid molecule encoding one of the biomarkers identified in Table A.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the one or more binding moieties each comprise or consist of a nucleic acid molecule.

### Claim 44 (depends on 42)

The method according to claim 42 wherein, the one or more binding moieties each comprise or consist of DNA, RNA, PNA, LNA, GNA, TNA or PMO.

### Claim 45 (depends on 42, 44)

The method according to claim 42 or 44, wherein the one or more binding moieties each comprise or consist of DNA.

### Claim 46 (depends on 42, 43, 44, 45)

The method according to any one of claims 42-45 wherein the one or more binding moieties are 5 to 100 nucleotides in length.

### Claim 47 (depends on 42, 43, 44, 45)

The method according to any one of claims 42-45 wherein the one or more nucleic acid molecules are 15 to 35 nucleotides in length.

### Claim 48 (depends on 43, 44, 45, 46, 47)

The method according to any one of claims 43-47 wherein the binding moiety comprises a detectable moiety.

### Claim 49 (depends on 48)

The method according to claim 48 wherein the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety (for example, a radioactive atom); or an enzymatic moiety.

### Claim 50 (depends on 49)

The method according to claim 49 wherein the detectable moiety comprises or consists of a radioactive atom.

### Claim 51 (depends on 50)

The method according to claim 50 wherein the radioactive atom is selected from the group consisting of technetium-99m, iodine-123, iodine-125, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, phosphorus-32, sulphur-35, deuterium, tritium, rhenium-186, rhenium-188 and yttrium-90.

### Claim 52 (depends on 49)

The method according to claim 49 wherein the detectable moiety of the binding moiety is a fluorescent moiety.

### Claim 53

The method according to any one of the preceding claims wherein, the sample provided in step (b), (d) and/or (f) is selected from the group consisting of unfractionated blood, plasma, serum, tissue fluid, pancreatic tissue, pancreatic juice, bile and urine.

### Claim 54 (depends on 53)

The method according to claim 53, wherein the sample provided in step (b), (d) and/or (f) is selected from the group consisting of unfractionated blood, plasma and serum.

### Claim 55 (depends on 53, 54)

The method according to claim 53 or 54, wherein the sample provided in step (b), (d) and/or (f) is plasma.

### Claim 56 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

An array for determining the presence of pancreatic cancer in an individual comprising one or more binding agent as defined in any one of claims 16 to 30.

### Claim 57 (depends on 56)

An array according to claim 56 wherein the one or more binding agents is capable of binding to all of the proteins defined in Table A.

### Claim 58

Use of one or more biomarkers selected from the group defined in Table A as a diagnostic marker for determining the presence of pancreatic cancer in an individual.

### Claim 59 (depends on 58)

The use according to claim 58 wherein all of the proteins defined in Table A are used as a diagnostic marker for determining the presence of pancreatic cancer in an individual.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 56, 58, 59)

A kit for determining the presence of pancreatic cancer comprising:
C) one or more first binding agent as defined in any one of claims 16 to 24 or an array according to claims 32 to 35 or claim 56 or 56;
D) instructions for performing the method as defined in any one of claims 1 to 36 or the use according to any one of claim 58 or 59.

### Claim 61 (depends on 35, 36, 37, 38, 39, 40, 61)

A kit according to claim 61 further comprising a second binding agent as defined in any one of claims 35 to 40.

### Claim 62

A method or use for determining the presence of pancreatic cancer in an individual substantially as described herein.

### Claim 63

An array or kit for determining the presence of pancreatic cancer in an individual substantially as described herein.
